Drug intelligence / Profile preview

FAUN-264G

Development stage: Preclinical
Lead developer: Fauna Bio
Modality: Small Molecules
Administration: Ophthalmic

Overview

FAUN-264G is a small molecule drug candidate developed by Fauna Bio for the treatment of retinal diseases, with a primary focus on eye diseases. The compound is currently in preclinical development. Specific details regarding its mechanism of action or molecular targets have not been disclosed as of the latest available information.

Beyond the preview

Go deeper on FAUN-264G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAUN-264G.

Explore the full profile